Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

2 source entries across 2 studies. This list may not include all unresolved or historical entries.

  • Prednisone (and methylprednisolone)Registry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Prednisone (and methylprednisolone)Registry intervention

    Linked study entry; product equivalence not established

    View study and source

Success Metrics

Completion Rate
0%(0/1)
Active Trials
2(67%)
Terminated
1(33%)

Phase Distribution

Phase 3
1
33%
Phase 1/2
1
33%
Phase 2
1
33%

Phase Distribution

0

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 1/2Combined phases
1(33.3%)
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

2

trials recruiting

Total Trials

3

all time

Status Distribution
Active(2)
Terminated(1)

Detailed Status

Recruiting1
Terminated1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
2
Success Rate
0.0%
Most Advanced
Phase 3

Trials by Phase

Phase 1/21 (33.3%)
Phase 21 (33.3%)
Phase 31 (33.3%)

Trials by Status

recruiting133%
terminated133%
active_not_recruiting133%

Recent Activity

2 active trials
Showing 3 of 3
recruitingphase_2

Early Vedolizumab as First-Line for Immune-Related Colitis Therapy Trial

NCT06841705
active_not_recruitingphase_1_2

The Efficacy and Safety of Treatment with Telitacicept in Antineutrophil Cytoplasmic Antibody-associated Nephritis (AAGN)

NCT06656962
terminatedphase_3

IMPROVE: Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy in ANCA Associated Systemic Vasculitis

NCT00307645

Clinical Trials (3)

Showing 3 of 3 trials
NCT06841705Phase 2

Early Vedolizumab as First-Line for Immune-Related Colitis Therapy Trial

Recruiting
NCT06656962Phase 1/2

The Efficacy and Safety of Treatment with Telitacicept in Antineutrophil Cytoplasmic Antibody-associated Nephritis (AAGN)

Active Not Recruiting
NCT00307645Phase 3

IMPROVE: Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy in ANCA Associated Systemic Vasculitis

Terminated

All 3 trials loaded

Drug Details

Intervention Type
Drug
Total Trials
3